Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F A Lemonnier

Showing results (71-80 of 78) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 78 results.
Immunogenetics|January 1, 1983
Transformation of LMTK- cells with purified HLA class I genes. II. Serologic characterization of HLA-A3 and CW3 moleculesF A Lemonnier, P C Dubreuil, C Layet, et al.
British Journal of Cancer|June 24, 2004
MAGE-A8 overexpression in transitional cell carcinoma of the bladder: identification of two tumour-associated antigen peptidesE Bar-Haim, A Paz, A Machlenkin, et al.
Journal of Virology|June 11, 1999
Immunogenicity of a human immunodeficiency virus (HIV) polytope vaccine containing multiple HLA A2 HIV CD8(+) cytotoxic T-cell epitopesT Woodberry, J Gardner, L Mateo, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 8, 1999
Cutting edge: expression of functional CD94/NKG2A inhibitory receptors on fetal NK1.1+Ly-49- cells: a possible mechanism of tolerance during NK cell developmentP V Sivakumar, A Gunturi, M Salcedo, et al.
Human Immunology|May 1, 1997
The diversity of antigen-specific TCR repertoires reflects the relative complexity of epitopes recognizedJ L Maryanski, J L Casanova, K Falk, et al.
Immunity|August 6, 1999
Direct assessment of MHC class I binding by seven Ly49 inhibitory NK cell receptorsT Hanke, H Takizawa, C W McMahon, et al.
European Journal of Immunology|October 30, 1999
H-2 class I knockout, HLA-A2.1-transgenic mice: a versatile animal model for preclinical evaluation of antitumor immunotherapeutic strategiesH Firat, F Garcia-Pons, S Tourdot, et al.
Diabetologia|April 25, 2012
Zinc transporter (ZnT)8(186-194) is an immunodominant CD8+ T cell epitope in HLA-A2+ type 1 diabetic patientsM Scotto, G Afonso, E Larger, et al.
Pageof 8

Showing results (71-80 of 78) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 78 results.
Immunogenetics|January 1, 1983
Transformation of LMTK- cells with purified HLA class I genes. II. Serologic characterization of HLA-A3 and CW3 moleculesF A Lemonnier, P C Dubreuil, C Layet, et al.
British Journal of Cancer|June 24, 2004
MAGE-A8 overexpression in transitional cell carcinoma of the bladder: identification of two tumour-associated antigen peptidesE Bar-Haim, A Paz, A Machlenkin, et al.
Journal of Virology|June 11, 1999
Immunogenicity of a human immunodeficiency virus (HIV) polytope vaccine containing multiple HLA A2 HIV CD8(+) cytotoxic T-cell epitopesT Woodberry, J Gardner, L Mateo, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 8, 1999
Cutting edge: expression of functional CD94/NKG2A inhibitory receptors on fetal NK1.1+Ly-49- cells: a possible mechanism of tolerance during NK cell developmentP V Sivakumar, A Gunturi, M Salcedo, et al.
Human Immunology|May 1, 1997
The diversity of antigen-specific TCR repertoires reflects the relative complexity of epitopes recognizedJ L Maryanski, J L Casanova, K Falk, et al.
Immunity|August 6, 1999
Direct assessment of MHC class I binding by seven Ly49 inhibitory NK cell receptorsT Hanke, H Takizawa, C W McMahon, et al.
European Journal of Immunology|October 30, 1999
H-2 class I knockout, HLA-A2.1-transgenic mice: a versatile animal model for preclinical evaluation of antitumor immunotherapeutic strategiesH Firat, F Garcia-Pons, S Tourdot, et al.
Diabetologia|April 25, 2012
Zinc transporter (ZnT)8(186-194) is an immunodominant CD8+ T cell epitope in HLA-A2+ type 1 diabetic patientsM Scotto, G Afonso, E Larger, et al.
Pageof 8